復星醫藥(02196.HK)與Insightec成立內地合資公司 拓磁波刀腦部治療系統
復星醫藥(02196.HK)宣布,旗下醫療器械事業部子公司與Insightec(醫視特)正式簽署合作協議,雙方將攜手在中國合資成立復星醫視特,將致力於磁共振引導聚焦超聲腦部治療系統(即「磁波刀」腦部治療系統)在中國市場的商業化拓展、臨床應用及研究,幫助帕金森病患者和特發性震顫患者重獲高質量生活。
此外,復星醫視特也將計劃與國內多家醫學中心建立戰略合作夥伴關係,進一步探索「磁波刀」未來在神經系統疾病中的應用潛力,惠及更廣泛的患者群體。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.